Keyphrases
Dendritic Cell Vaccine
100%
Cyclophosphamide
100%
Treg
80%
Dendritic Cells
60%
Autologous Dendritic Cells
40%
ELISpot Assay
40%
Immune Response
40%
Clinical Response
40%
Proliferation Assay
40%
Immune Monitoring
40%
Therapeutic Potential
20%
Vaccination
20%
Clinical Benefit
20%
Metastatic Melanoma
20%
In Cancer
20%
Cancer Immunotherapy
20%
Tumor Regression
20%
Without Chemotherapy
20%
Immune Parameters
20%
Clinical Setting
20%
Progressive Disease
20%
Blood Samples
20%
Phase I Trial
20%
Flow Cytometry
20%
Immune Regulation
20%
Best Response
20%
Intradermal Injection
20%
Addition Effect
20%
Regulatory Mechanism
20%
Patient Cohort
20%
Regulatory T Cells
20%
Stable Disease
20%
Clinical Effect
20%
Immunological Effects
20%
Computed Tomography
20%
Medicine and Dentistry
Messenger RNA
100%
Dendritic Cell Vaccine
100%
Melanoma
100%
Cyclophosphamide
100%
Dendritic Cell
83%
Immunity
50%
Immune Response
33%
Cancer Immunotherapy
16%
Tumor Regression
16%
Progressive Disease
16%
Immunocompetent Cell
16%
Flow Cytometry
16%
Intradermal Drug Administration
16%
Diseases
16%
Regulatory T Cell
16%
Phase I Trials
16%
Pharmacology, Toxicology and Pharmaceutical Science
Dendritic Cell Vaccine
100%
Melanoma
100%
Cyclophosphamide
100%
Messenger RNA
100%
Diseases
33%
Phase I Trials
16%
Tumor Regression
16%
Malignant Neoplasm
16%
Immunotherapy
16%
Flow Cytometry
16%
Chemotherapy
16%
Immunology and Microbiology
Cyclophosphamide
100%
Dendritic Cell Vaccine
100%
Dendritic Cell
83%
Regulatory T Cell
83%
Immunity
50%
Immune Response
33%
Immunocompetent Cell
16%
X-Ray Computed Tomography
16%
Cancer Immunotherapy
16%